So Yeon Kim, Hyunyee Yoon, Seung Ho Choi, Jaeyoung Cho
{"title":"血清基质金属蛋白酶-9作为阻塞性睡眠呼吸暂停严重程度的潜在生物标志物。","authors":"So Yeon Kim, Hyunyee Yoon, Seung Ho Choi, Jaeyoung Cho","doi":"10.1007/s11325-025-03287-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to investigate the associations between serum matrix metalloproteinase (MMP)-2 and MMP-9 levels and obstructive sleep apnea (OSA) severity with a focus on nocturnal hypoxemia.</p><p><strong>Methods: </strong>The OSA patients (n = 105) were recruited from a prospective sleep apnea cohort after polysomnography, with 27 healthy volunteers as the controls. OSA severity was assessed via the apnea-hypopnea index (AHI) and percent night time with SpO<sub>2</sub> < 90% (T90).</p><p><strong>Results: </strong>The serum MMP-9 levels were significantly higher in the OSA patients (AHI ≥ 5/h, 68.8 ± 44.9 ng/mL) than the controls (49.0 ± 18.6 ng/mL, p < 0.001). The MMP-2 levels showed no significant differences. When grouped into T90 quartiles, the MMP-9 levels were higher in the OSA patients in the highest quartile compared to those in the lowest quartile or the controls (90.6 ± 56.3 ng/mL vs. 56.9 ± 31.9 ng/mL, p = 0.022; 90.6 ± 56.3 ng/mL vs. 49.0 ± 18.6 ng/mL, p = 0.002, respectively). The MMP-9 levels correlated with T90 and the AHI (r = 0.36, p < 0.001; r = 0.35, p < 0.001, respectively). Multiple linear regression confirmed a significant association between MMP-9 and T90 after adjusting for body mass index, smoking status, and comorbidities (β = 0.53, p = 0.013). A similar association was observed for the AHI (β = 0.48, p = 0.019).</p><p><strong>Conclusion: </strong>We concluded that serum MMP-9 levels are independently associated with OSA severity, particularly with T90 and the AHI, which suggests that MMP-9 could be a biomarker for OSA severity.</p>","PeriodicalId":21862,"journal":{"name":"Sleep and Breathing","volume":"29 2","pages":"134"},"PeriodicalIF":2.0000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928356/pdf/","citationCount":"0","resultStr":"{\"title\":\"Serum matrix metalloproteinase-9 as a potential biomarker for obstructive sleep apnea severity.\",\"authors\":\"So Yeon Kim, Hyunyee Yoon, Seung Ho Choi, Jaeyoung Cho\",\"doi\":\"10.1007/s11325-025-03287-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>We aimed to investigate the associations between serum matrix metalloproteinase (MMP)-2 and MMP-9 levels and obstructive sleep apnea (OSA) severity with a focus on nocturnal hypoxemia.</p><p><strong>Methods: </strong>The OSA patients (n = 105) were recruited from a prospective sleep apnea cohort after polysomnography, with 27 healthy volunteers as the controls. OSA severity was assessed via the apnea-hypopnea index (AHI) and percent night time with SpO<sub>2</sub> < 90% (T90).</p><p><strong>Results: </strong>The serum MMP-9 levels were significantly higher in the OSA patients (AHI ≥ 5/h, 68.8 ± 44.9 ng/mL) than the controls (49.0 ± 18.6 ng/mL, p < 0.001). The MMP-2 levels showed no significant differences. When grouped into T90 quartiles, the MMP-9 levels were higher in the OSA patients in the highest quartile compared to those in the lowest quartile or the controls (90.6 ± 56.3 ng/mL vs. 56.9 ± 31.9 ng/mL, p = 0.022; 90.6 ± 56.3 ng/mL vs. 49.0 ± 18.6 ng/mL, p = 0.002, respectively). The MMP-9 levels correlated with T90 and the AHI (r = 0.36, p < 0.001; r = 0.35, p < 0.001, respectively). Multiple linear regression confirmed a significant association between MMP-9 and T90 after adjusting for body mass index, smoking status, and comorbidities (β = 0.53, p = 0.013). A similar association was observed for the AHI (β = 0.48, p = 0.019).</p><p><strong>Conclusion: </strong>We concluded that serum MMP-9 levels are independently associated with OSA severity, particularly with T90 and the AHI, which suggests that MMP-9 could be a biomarker for OSA severity.</p>\",\"PeriodicalId\":21862,\"journal\":{\"name\":\"Sleep and Breathing\",\"volume\":\"29 2\",\"pages\":\"134\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-03-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928356/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sleep and Breathing\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11325-025-03287-2\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep and Breathing","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11325-025-03287-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Serum matrix metalloproteinase-9 as a potential biomarker for obstructive sleep apnea severity.
Purpose: We aimed to investigate the associations between serum matrix metalloproteinase (MMP)-2 and MMP-9 levels and obstructive sleep apnea (OSA) severity with a focus on nocturnal hypoxemia.
Methods: The OSA patients (n = 105) were recruited from a prospective sleep apnea cohort after polysomnography, with 27 healthy volunteers as the controls. OSA severity was assessed via the apnea-hypopnea index (AHI) and percent night time with SpO2 < 90% (T90).
Results: The serum MMP-9 levels were significantly higher in the OSA patients (AHI ≥ 5/h, 68.8 ± 44.9 ng/mL) than the controls (49.0 ± 18.6 ng/mL, p < 0.001). The MMP-2 levels showed no significant differences. When grouped into T90 quartiles, the MMP-9 levels were higher in the OSA patients in the highest quartile compared to those in the lowest quartile or the controls (90.6 ± 56.3 ng/mL vs. 56.9 ± 31.9 ng/mL, p = 0.022; 90.6 ± 56.3 ng/mL vs. 49.0 ± 18.6 ng/mL, p = 0.002, respectively). The MMP-9 levels correlated with T90 and the AHI (r = 0.36, p < 0.001; r = 0.35, p < 0.001, respectively). Multiple linear regression confirmed a significant association between MMP-9 and T90 after adjusting for body mass index, smoking status, and comorbidities (β = 0.53, p = 0.013). A similar association was observed for the AHI (β = 0.48, p = 0.019).
Conclusion: We concluded that serum MMP-9 levels are independently associated with OSA severity, particularly with T90 and the AHI, which suggests that MMP-9 could be a biomarker for OSA severity.
期刊介绍：
The journal Sleep and Breathing aims to reflect the state of the art in the international science and practice of sleep medicine. The journal is based on the recognition that management of sleep disorders requires a multi-disciplinary approach and diverse perspectives. The initial focus of Sleep and Breathing is on timely and original studies that collect, intervene, or otherwise inform all clinicians and scientists in medicine, dentistry and oral surgery, otolaryngology, and epidemiology on the management of the upper airway during sleep.
Furthermore, Sleep and Breathing endeavors to bring readers cutting edge information about all evolving aspects of common sleep disorders or disruptions, such as insomnia and shift work. The journal includes not only patient studies, but also studies that emphasize the principles of physiology and pathophysiology or illustrate potentially novel approaches to diagnosis and treatment. In addition, the journal features articles that describe patient-oriented and cost-benefit health outcomes research. Thus, with peer review by an international Editorial Board and prompt English-language publication, Sleep and Breathing provides rapid dissemination of clinical and clinically related scientific information. But it also does more: it is dedicated to making the most important developments in sleep disordered breathing easily accessible to clinicians who are treating sleep apnea by presenting well-chosen, well-written, and highly organized information that is useful for patient care.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
